Foamix acquires rights to aerosol device

According to the license agreement, Foamix has the exclusive rights to use the dual-chamber device for all topical and intra-vaginal drug products requiring prescription.

The device is protected by US patent number 6,305,578, EP 1075325 and JP 2000-600768; and Foamix has its own patent applications, covering a broad spectrum of foam vehicles and drugs that can be incorporated in this device.

Dov Tamarkin, CEO of Foamix, said: “This license will enable us to incorporate two or more active agents in the same pharmaceutical product, with no stability concerns. We are committed to continuing progress at the forefront of topical therapy, and our ability to develop stable, safe and effective combination drugs will provide added value for Foamix and for our industry partners.”